This study demonstrated that mCPT-1 expression was significantly decreased in NAFLD rats and that β3-AR agonist treatment could upregulate mCPT-1 expression, playing a role in reducing NAFLD liver steatosis. The gene discussed is CPT1B; the disease is metabolic dysfunction-associated steatotic liver disease.